Literature DB >> 28042299

Antimalarial Potential of Carica papaya and Vernonia amygdalina in Mice Infected with Plasmodium berghei.

Oche Okpe1, Nathan Habila2, Joseph Ikwebe1, Vincent A Upev1, Stanley I R Okoduwa3, Omiagocho T Isaac1.   

Abstract

The study determined if administration of Vernonia amygdalina and Carica papaya plants provides synergistic effects in ameliorating plasmodium infection in mice. Thirty mice (17.88-25.3 g) were divided into 6 groups of 5 mice each. Group 1 was normal control, while groups 2-6 were intraperitoneally inoculated 2.5 × 107Plasmodium berghei parasitized red blood cell, followed by daily administration of 350 mg/kg aqueous leaf extracts after establishment of infection. Group 2 was disease control, while group 6 was treated with standard drug for four consecutive days. The results showed significant (P < 0.05) reduction in percentage of parasite load between the infected treatment groups and disease control group at day 3 after infection, which remained consistent until the end of the experiment. All infected treated groups showed significant (P < 0.05) increases in RBC and PCV recovery compared to the disease control, with the exception of WBC. There was insignificant (P > 0.05) change in mean body weight of all treated groups except in disease control group. Histological studies of the infected mice indicate recovery of hepatic cells from congested black pigmentation. The reduction in parasite load and recovery of hepatic cell damage/hematological parameters were induced by these plant extracts. This highlighted the important usage of the plant in traditional remedy of malaria infection.

Entities:  

Year:  2016        PMID: 28042299      PMCID: PMC5153544          DOI: 10.1155/2016/8738972

Source DB:  PubMed          Journal:  J Trop Med        ISSN: 1687-9686


1. Introduction

Malaria remains one of the deadliest infectious diseases, caused by protozoan parasite of the genus Plasmodium [1]. Available therapeutic agents are already limited in their efficacy, while drug resistance threatens the ability to prevent and treat the infection [1]. Malaria is the leading cause of illness and death in sub-Saharan Africa with an annual mortality of approximately one million children under five [2]. In Nigeria and the rest of the world, malaria infection continues to pose a major health challenge. In view of resistance of the parasite to antimalarial drug therapy, which leads to drug failure, new drugs or drug combinations are urgently required for the treatment of malaria infections from traditional medicinal plants [3]. Traditional medicinal plants play an important role in the medical system in Nigeria; however, plant materials remain an important resource to combat serious diseases in the world. Currently used plants have always been considered to be a possible alternative and rich source of new drugs, and some of the antimalarial drugs in use today such as quinine and artemisinin were either obtained directly from plants or developed using chemical structures of plant-derived compounds as templates [4]. The uses of synthetic antimalarial drugs are among the main ways to treat malaria and are effective in controlling parasite load. However, the practical application of the majority of these therapeutic agents remains restricted owing to their limited action, pharmacokinetic properties, secondary failure rate, and accompanying side effects [5]. With the increasing incidence of the disease in urban/rural population throughout the world, there is clear need for development of indigenous, inexpensive botanical sources for antimalarial crude or purified drugs [5]. Vernonia amygdalina Del belongs to the family Asteraceae; its common name is bitter leaf. It is a perennial shrub of 2–5 m in height that grows throughout tropical Africa [6]. The leaf and stem are acclaimed to be one of the most used medicinal plants in traditional practice [7]. Carica papaya Linn belongs to the Caricaceae family and is commonly known as pawpaw [8]. The leaf of Carica papaya in combination with Vernonia amygdalina is used traditionally to treat infection [7, 9]. In traditional medicine, herbal practitioners use V. amygdalina and C. papaya in Nigeria as anthelmintic, antimalaria, digestive tonic, appetizer, antihemolytic, antifungal, and antijaundice agents. The leaf infusion is used in treatment of urinary disorders and gonorrhea. The fresh leaves are used in dressing of wounds or as antidysentery agent and against chronic diarrhea or as sedative and as cure for pile and wounds of the urinary tracts and several other ailments [9]. The plant extracts have been scientifically proven to function as antibacterial [7], antifungal [7, 10], anticancer/tumor [11, 12], and antiplasmodial agents [13, 14]. While the physiological role of some plant active principle(s) has been intensively studied and their functions in health and disease conditions have been recognized, it is still a focus of pharmaceutical research in the development of agent that can effectively treat malaria and many other diseases, hence the need to study the efficacy of V. amygdalina and C. papaya in living systems in order to foster information regarding its medical applications in malarial infection.

2. Materials and Methods

2.1. Plant Samples Collection and Identification

Fresh leaves of Vernonia amygdalina and Carica papaya were collected in November 2015, from Federal Low Cost Housing Estate, Makurdi, Nigeria. The plants were identified and authenticated by a taxonomist in the Department of Biological Sciences, University of Agriculture, Makurdi, Nigeria.

2.2. Experimental Animals

Adult mice (17.88–25.3 g) of both sexes were obtained from the Laboratory Animal House, College of Health Sciences, Benue State University, Makurdi, Nigeria. The animals were acclimatized for 2 weeks under standard environmental conditions. The temperature and humidity were maintained at 25°C and 50%, respectively. Dark and light cycles were maintained at 12 hrs each. They had access to standard commercial rat pellets (UAC Grand Cereal Ltd., Jos, Nigeria) and water ad libitum. The animals were used in accordance with the guideline and recommendation of the ethics committee on the use of animals for research of the University of Agriculture, Makurdi, Nigeria.

2.3. Equipment/Reagents

The following equipment and reagents were used: Olympus microscope, hemocytometer with aspirating pipette, capillary tube, microhematocrit centrifuge, PCV reader, cover slip and slides, and water bath. Turk's fluid for WBC, Dacie's fluid for RBC, and Giemsa stain were purchased from Sigma-Andrich Chemical Company (St. Louis, USA). All other chemicals and reagents used for this study were of analytical grade.

2.4. Preparation of Plant Sample

The collected samples were rinsed in clean water and shade dried at room temperature for two weeks. The dry plants sample was ground into powder using pestle and mortar. The powder obtained was then used to prepare the extracts.

2.5. Aqueous Extraction

Exactly 100 g of the dried powder was weighed out and soaked in the solvent (water) with the solute-solvent proportion of 1 : 10. The extraction was by cold maceration at room temperature with intermittent shaking at 3-hour intervals for 48 hours. Whatman filter paper of 8 μm was used to filter the extract. The filtrate obtained was concentrated in temperature regulated water bath at 45°C.

2.6. Lethality (LD50) Test

The mean lethal dose (LD50) of the aqueous extracts was determined in mice (weighing 20–30 g) using the arithmetic-geometric-harmonic (AGH) methods of rough estimation as modified by Saganuwan [15].

2.7. Malaria Parasite

The malaria parasite (Chloroquine sensitive Plasmodium berghei (Nk65)) was obtained from the Faculty of Veterinary Medicine, Ahmadu Bello University (ABU), Zaria.

2.8. Parasite Inoculation

Plasmodium berghei parasitized erythrocytes were obtained from the tail of the donor mice and were diluted with 0.9% normal saline. Mice were inoculated intraperitoneally with 0.5 mL blood suspension containing 2.5 × 107 parasitized erythrocytes on day 0 and were monitored for manifestation of parasitemia for 4 days without treatment. The mice were randomly divided into 6 groups of five (5) mice per group and treated for 4 consecutive days with daily doses of the extracts (350 mg/kg b.w) and standard antimalarial drug (halofantrine, 25 mg/kg b.w) by oral route.

2.9. Animal Grouping and Treatment

Group 1: negative control, not infected with P. berghei and not treated Group 2: positive control, infected with P. berghei but not treated Group 3: infected with P. berghei and treated with 350 mg/kg C. papaya extract Group 4: infected with P. berghei and treated with 350 mg/kg V. amygdalina extract Group 5: infected with P. berghei and treated with 350 mg/kg combined extracts of C. papaya and V. amygdalina in ratio 1 : 1 Group 6: infected with P. berghei and treated with antimalarial drug (halofantrine, 25 mg/kg)

2.10. Hematological Analysis

The percentages of parasitized erythrocytes levels were determined as described by Brown [16], using a microscopic examination of thin blood smears made on microscopic slide. The packed cell volume was assayed according to the method described by Coles [17]. The RBC and WBC count was estimated according to the protocol of Brown [16], using the Neubauer haemocytometer.

2.11. Histological Analysis

At the end of the experiment, all the mice were anaesthetized using chloroform and bled by cardiac puncture. The hepatic tissues were dissected out of all the mice and washed on ice cold saline immediately. A portion of the tissue was fixed in 10% formalin fixative solution for histological studies as described by Strate et al. [18].

2.12. Statistical Analysis

The analysis was carried out in triplicate for all determinations and the results were expressed as mean ± SEM. The SPSS program (version 20.0 SPSS Inc., Chicago, IL, USA) was used for the analysis of variance, followed by the new Duncan's multiple range tests for multiple comparisons of the means [19]. P < 0.05 between mean values was considered statistically significant.

3. Results

The results of this study show that aqueous leaf extracts of V. amygdalina and C. papaya displayed antimalarial activity in an infected mouse when compared to the infected, untreated control. Figure 1 reveals the percentage of parasitized erythrocytes of mice infected with P. berghei. The groups infected with P. berghei developed parasitemia after infection. The percentage of parasitized erythrocytes in the infected untreated group (Group 2) was significantly (P < 0.05) increased on day 9 compared to postinfection day (within group) and other groups (between groups), respectively. The significant (P < 0.05) reduction in parasite load was more pronounced in groups 3 and 6, respectively.
Figure 1

The percentage of parasitized erythrocytes in mice infected with P. berghei and treated with aqueous leaf extracts of V. amygdalina and C. papaya, and halofantrine.

Table 1 shows the mean RBC, PCV, and WBC count of mice infected with P. berghei and subsequently treated with aqueous extracts of C. papaya, V. amygdalina, combined C. P. + V. A., and halofantrine. There was significant (P < 0.05) decrease in mean RBC count and PCV in all the experimental groups after infection compared to normal control group. However, as treatment commenced, there was an observed significant (P < 0.05) increase in mean RBC count and PCV within groups in all the treated groups (except RBC in group 4) compared to the infected, untreated control group. The mean white blood cells count of all the groups infected with P. berghei was significantly (P < 0.05) increased after infection compared to the normal control. Increase in WBC was significantly reduced upon administration of the different regimen of extracts to infected groups.
Table 1

The red blood cell and white blood cell count of mice infected with P. berghei and treated with aqueous leaf extracts of V. amygdalina, C. papaya, and halofantrine.

ParametersGroupsPreinfectionDay 0Day 3Day 6Day 9
RBC (×1012/l)GRP I13.60 ± 0.47b 13.08 ± 0.53b 11.70 ± 0.74ab 10.88 ± 0.27a 11.48 ± 0.62a
GRP II12.10 ± 0.70c 6.50 ± 1.92b 1.23 ± 0.21a 1.40 ± 0.51a 2.15 ± 0.33a
GRP III9.84 ± 0.49c 5.44 ± 0.24b 2.90 ± 0.05a 4.23 ± 0.11a 5.23 ± 0.18b
GRP IV10.26 ± 0.47c 5.42 ± 0.72b 2.90 ± 0.72a 2.37 ± 0.29a 5.57 ± 0.23b
GRP V12.80 ± 1.37c 4.42 ± 0.19b 0.93 ± 0.23a 2.30 ± 0.31a
GRP VI11.56 ± 0.21e 2.70 ± 0.22b 1.63 ± 0.27a 5.45 ± 0.17c 6.45 ± 0.22d

PCV (%)GRP I50.40 ± 1.46b 44.20 ± 2.33ab 44.20 ± 4.80ab 46.20 ± 1.95ab 38.60 ± 2.15a
GRP II52.00 ± 1.87d 43.20 ± 0.73c 30.33 ± 4.37b 33.50 ± 1.50b 17.50 ± 2.50a
GRP III48.60 ± 1.40c 43.20 ± 0.73c 20.75 ± 1.85a 41.50 ± 2.53bc 32.75 ± 5.34b
GRP IV43.20 ± 2.52b 44.60 ± 0.81b 29.50 ± 2.06a 26.33 ± 5.78a 30.00 ± 0.00a
GRP V47.20 ± 1.71d 39.20 ± 1.24c 23.00 ± 0.00b 18.00 ± 0.00a
GRP VI49.80 ± 0.48d 34.80 ± 1.85b 27.50 ± 2.90a 46.50 ± 1.50cd 45.50 ± 0.50c

WBC (×109/l)GRP I4.68 ± 0.59ab 4.32 ± 0.56a 4.56 ± 0.55ab 7.04 ± 0.32bc 6.04 ± 0.63c
GRP II4.20 ± 1.86a 6.75 ± 1.24a 17.93 ± 4.45a 13.00 ± 0.25ab 13.20 ± 0.38b
GRP III6.08 ± 0.83a 6.30 ± 0.59ab 8.13 ± 1.75ab 6.73 ± 1.17b 8.93 ± 0.38b
GRP IV6.36 ± 1.32ab 5.92 ± 1.16a 11.27 ± 1.89c 10.33 ± 5.34bc 5.80 ± 0.00ab
GRP V8.00 ± 1.76a 13.90 ± 0.65b 15.2 ± 0.00b 7.60 ± 0.00a
GRP VI4.68 ± 1.42a 15.36 ± 1.42c 12.10 ± 1.89b 4.60 ± 0.51ab 7.80 ± 0.13ab

Values are expressed as mean ± SEM of five replicate determinations. Values with different superscript along the rows are significantly different at P < 0.05.

The body weight of all the experimental groups was presented in Figure 2. There was significant (P < 0.05) increase in the body weight gain throughout the postinfection period in groups 1, 3, and 6 compared to the preinfection day. However, no significant increase was observed in groups 2, 4, and 5 when compared to the preinfection day.
Figure 2

The mean body weight of mice infected with P. berghei and treated with aqueous leaf extracts of V. amygdalina, C. papaya, and halofantrine. Black colour indicates preinfection; red colour indicates day 9, except in Grp 5 (indicating day 6).

Figure 3 shows the histological section of the hepatocyte of mice infected with P. berghei and treated with aqueous extracts of C. papaya, V. amygdalina, combined C. P. + V. A., and halofantrine. Figure 3(a) is the normal control mice with normal architecture of hepatic cells and reference standard. Figure 3(b) is the malarial control mice with complete depletion of hepatic cells by P. berghei. Here, the figure revealed prominent sinusoids and sinusoidal spaces, along with areas of necrosis. Figure 3(c) is the representative hepatocyte from infected mice treated with 350 mg/kg b.w of the extracts. In this figure, there was a slight restoration of diffused proliferated hepatic cells. Figure 3(d) is the infected mice treated with 25 mg/kg b.w halofantrine; this shows slight restoration of diffused proliferated hepatic cells.
Figure 3

Representative central vein of the hepatic cells of the parasitic mice treated with leaf extracts of V. amygdalina, C. papaya, and halofantrine.

4. Discussion

The existence of experimental animal models of a disease aids not only in the understanding of the pathophysiology of such disease, but also in the development of drug candidate [20]. Therefore, screening for antimalarial activity of plant crude extracts is the first step in isolation of new molecules with potent activity [21, 22]. The results clearly indicate that the individual administration of aqueous leaf extract of C. papaya, V. amygdalina, and the combination of both plants significantly (P < 0.05) decreased parasite load in mice and enhanced their survival. There are many bioactive constituents present in both extracts and hence, at present, it is not certain, which is/are responsible for the observed effects. However, some reports have shown that flavonoids, tannins, saponins, and other phytoconstituents may play some roles in the inhibition of malaria parasites in infected animals [23, 24]. The observed parasitemia in the experimental mice when treated separately with single doses and with a combined dose of C. papaya and V. amygdalina synergistically decreases along with halofantrine on day 9 after establishment of infection, compared with the disease control which is characterized by excessive parasite growth, exaggerated immune reactions, or a combination of both causing severe pathology and death, which is detrimental to both parasite and host. Thus, the findings of Saganuwan et al. [25] that many Nigerian plants can be used for the treatment of malaria and that infection with P. berghei is almost fatal with death occurring within 1–3 weeks are corroborated[25]. The decrease in PCV and RBC and increase in WBC of all the infected groups after infections are in conformity with previous reports, documenting reduced serum PCV, RBC, and an increased WBC levels in malarial subjects [5]. In this study, administration of aqueous leaf extracts of C. papaya, V. amygdalina, and the combined extracts significantly reduced WBC and triggered an increase in PCV as a result of increased production of RBC, thus, suppressing hemolytic damage to RBC. The increase in body weight of the infected groups of mice and the noninfected group disagrees with the report of Saganuwan and Onyeyili [5], indicating that P. berghei decreases body weight. The increase in body weight observed in this study may be due to constant feeding of the animals during the experimental period. Histological examination of the liver cells in the treated groups showed the inability of the extract to clear the entire parasite inclusion from circulation and repair the hepatocyte, which agrees with the work of Stenad et al. [26], who stated that hepatic inclusions are defined as intracellular aggregates of stainable substances which represent established hallmarks of their respective human disorder. Signs of regeneration/repairs of tissues using medicinal plants have been reported in other works [27, 28], which are consistent with the present study. Thus, tissue repairs or therapy may offer therapeutic benefit in disease conditions.

5. Conclusion

In conclusion, the finding revealed that the reduction in parasite load and recovery of hepatic cell damage/hematological parameters were induced by the plant extracts and thus gave credence to the usage of the plant traditionally for the treatment of malaria.
  12 in total

1.  In vivo antimalarial activity of Vernonia amygdalina.

Authors:  Anthonia O Abosi; Benjamin H Raseroka
Journal:  Br J Biomed Sci       Date:  2003       Impact factor: 3.829

2.  Antimalarial compounds from Grewia bilamellata.

Authors:  Cuiying Ma; Hong Jie Zhang; Ghee Teng Tan; Nguyen Van Hung; Nguyen Manh Cuong; D Doel Soejarto; Harry H S Fong
Journal:  J Nat Prod       Date:  2006-03       Impact factor: 4.050

3.  Microcirculatory function and tissue damage is improved after therapeutic injection of bovine hemoglobin in severe acute rodent pancreatitis.

Authors:  Tim Strate; Oliver Mann; Helge Kleinhans; Skelkim Rusani; Claus Schneider; Emre Yekebas; Marc Freitag; Thomas Standl; Christian Bloechle; Jakob R Izbicki
Journal:  Pancreas       Date:  2005-04       Impact factor: 3.327

4.  Bioactive sesquiterpene lactones from the leaves of Vernonia amygdalina.

Authors:  P Erasto; D S Grierson; A J Afolayan
Journal:  J Ethnopharmacol       Date:  2006-02-03       Impact factor: 4.360

5.  Activity markers of the anti-breast carcinoma cell growth fractions of Vernonia amygdalina extracts.

Authors:  Daniel A Oyugi; Xuan Luo; Ken S Lee; Brandon Hill; Ernest B Izevbigie
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-28

6.  Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.

Authors:  Nobutaka Kato; Eamon Comer; Tomoyo Sakata-Kato; Arvind Sharma; Manmohan Sharma; Micah Maetani; Jessica Bastien; Nicolas M Brancucci; Joshua A Bittker; Victoria Corey; David Clarke; Emily R Derbyshire; Gillian L Dornan; Sandra Duffy; Sean Eckley; Maurice A Itoe; Karin M J Koolen; Timothy A Lewis; Ping S Lui; Amanda K Lukens; Emily Lund; Sandra March; Elamaran Meibalan; Bennett C Meier; Jacob A McPhail; Branko Mitasev; Eli L Moss; Morgane Sayes; Yvonne Van Gessel; Mathias J Wawer; Takashi Yoshinaga; Anne-Marie Zeeman; Vicky M Avery; Sangeeta N Bhatia; John E Burke; Flaminia Catteruccia; Jon C Clardy; Paul A Clemons; Koen J Dechering; Jeremy R Duvall; Michael A Foley; Fabian Gusovsky; Clemens H M Kocken; Matthias Marti; Marshall L Morningstar; Benito Munoz; Daniel E Neafsey; Amit Sharma; Elizabeth A Winzeler; Dyann F Wirth; Christina A Scherer; Stuart L Schreiber
Journal:  Nature       Date:  2016-09-07       Impact factor: 49.962

7.  In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum.

Authors:  L K Basco; S Mitaku; A L Skaltsounis; N Ravelomanantsoa; F Tillequin; M Koch; J Le Bras
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

8.  Antimalaria Effect of the Ethanolic Stem Bark Extracts of Ficus platyphylla Del.

Authors:  Isma'il Shittu; Amlabu Emmanuel; Andrew Jonathan Nok
Journal:  J Parasitol Res       Date:  2011-11-24

9.  Diversity and utilization of antimalarial ethnophytotherapeutic remedies among the Kikuyus (Central Kenya).

Authors:  Grace N Njoroge; Rainer W Bussmann
Journal:  J Ethnobiol Ethnomed       Date:  2006-02-01       Impact factor: 2.733

10.  Epidemiology of malaria in the forest-savanna transitional zone of Ghana.

Authors:  Seth Owusu-Agyei; Kwaku Poku Asante; Martin Adjuik; George Adjei; Elizabeth Awini; Mohammed Adams; Sam Newton; David Dosoo; Dominic Dery; Akua Agyeman-Budu; John Gyapong; Brian Greenwood; Daniel Chandramohan
Journal:  Malar J       Date:  2009-09-28       Impact factor: 2.979

View more
  5 in total

1.  In vivo antiplasmodial activities and acute toxicity assessment of two plant cocktail extracts commonly used among Southwestern Nigerians.

Authors:  Rachel Omagha; Emmanuel Taiwo Idowu; Chibuisi Gideon Alimba; Olubunmi Adetoro Otubanjo; Wellington Aghoghovwia Oyibo; Esther Oluwatoyin Agbaje
Journal:  J Parasit Dis       Date:  2021-09-14

2.  Natural Products as Sources of Antimalarial Drugs: Ethnobotanical and Ethnopharmacological Studies.

Authors:  Oluwole Solomon Oladeji; Abimbola Peter Oluyori; Deborah Temitope Bankole; Tokunbo Yemisi Afolabi
Journal:  Scientifica (Cairo)       Date:  2020-05-09

Review 3.  The Future of Carica papaya Leaf Extract as an Herbal Medicine Product.

Authors:  Maywan Hariono; Jeffry Julianus; Ipang Djunarko; Irwan Hidayat; Lintang Adelya; Friska Indayani; Zerlinda Auw; Gabriel Namba; Pandu Hariyono
Journal:  Molecules       Date:  2021-11-17       Impact factor: 4.411

Review 4.  Antimicrobial Importance of Medicinal Plants in Nigeria.

Authors:  Harriet U Ugboko; Obinna C Nwinyi; Solomon U Oranusi; Toluwase H Fatoki; Conrad A Omonhinmin
Journal:  ScientificWorldJournal       Date:  2020-09-22

Review 5.  Carica papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions.

Authors:  X Y Lim; J S W Chan; N Japri; J C Lee; T Y C Tan
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-07       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.